IL17A and hypertensive disorder: Since IL-17A is linked to Ang II induced HTN, renal dysfunction, and renal sodium transporter modulators, studies suggest that antibodies directed against IL-17A or the IL-17RA receptor subunit may be a novel adjunct hypertension therapy [141].